КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ ТЕРАПИИ МЕТАСТАТИЧЕСКОГО НЕМЕЛКО– КЛЕТОЧНОГО РАКА ЛЕГКОГО ДЕМОНСТРИРУЮТ МНОГООБЕЩАЮЩИЕ РЕЗУЛЬТАТЫ: КОНГРЕСС ASCO 2022

Abstract

Lung cancer (LC) is a commonly diagnosed malignant tumor that annually claims the lives of about 1.8 million peoples. In the Russian Federation, the group of tumors of the respiratory organs: trachea, bronchi and lung occupies the third place (9.4%, both sexes) in the structure of oncological morbidity after malignant neoplasms of the skin with melanoma (15.0%), breast (11.6% ). Up to 80% of detected malignant lung tumors are non-small cell carcinoma (NSCLC). Among patients with NSCLC, stage IIIB-IV of the process is diagnosed in 70% of cases. The median survival of patients in this group is 4-5 months, and only 10% of them survive 1 year from the moment of diagnosis. This study explored the most advanced clinical developments in the treatment of metastatic NSCLC discussed at the ASCO Annual Congress – 2022: new treatment options for mNSCLC with KRAS mutations and other targeted therapy strategies for mNSCLC. The reviewed clinical developments on targeted combination therapy for metastatic NSCLC show promising results and an acceptable drug safety profile for its personalized administration to patients after progression under standard treatment conditions. Presented at ASCO – 2022, the results of clinical trials of the latest drug molecules indicate their serious antitumor efficacy. Personalized methods of selective suppression of specific effector pathways of oncogenesis have certain clinical advantages.